PPARGC1A and Alzheimer disease: This study suggests a possible new approach for the treatment of AD, based on the preservation of the mitochondrial structure which open a new space of study centered on the modulation of PGC-1α/SIRT1 signaling, by PGC-1α deacetylation promotors, as new pharmacological tools to promote neuroprotection.